Iowa is currently home to 804 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Iowa City, Des Moines, Sioux City and West Des Moines. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Single-Sided Deafness in the Medicare Population
Recruiting
The purpose of this study is to evaluate the safety and effectiveness of cochlear implantation in adults 65 years of age and older.
Gender:
ALL
Ages:
65 years and above
Trial Updated:
08/06/2024
Locations: University of Iowa Hospitals and Clinics, Iowa City, Iowa
Conditions: Hearing Loss, Unilateral
Biologic Abatement and Capturing Kids' Outcomes and Flare Frequency in Juvenile Spondyloarthritis
Recruiting
This randomized pragmatic trial will generate knowledge about strategies used to de-escalate tumor necrosis factor inhibitor (TNFi) therapy in patients with juvenile spondyloarthritis with sustained inactive disease and are treated at one of the 29 participating pediatric healthcare systems. This open label study will be conducted in the setting of routine clinical care and will compare the risk and timing of flare (Aim 1) and patients' lived experiences (Aim 2) across three arms.
Gender:
ALL
Ages:
Between 8 years and 21 years
Trial Updated:
08/02/2024
Locations: University of Iowa Stead Family Children's Hospital, Iowa City, Iowa
Conditions: Juvenile Spondyloarthritis
ABTECT-2 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -2
Recruiting
This is a multicenter, randomized, placebo controlled study to evaluate the efficacy and safety of ABX464 given at 25 or 50 mg QD in inducing clinical remission in subjects with moderately to severely active ulcerative colitis who have inadequate response, no response, a loss of response, or an intolerance to either conventional therapies \[corticosteroids, immunosuppressant (i.e. azathioprine, 6-mercaptopurine, methotrexate)\] and/or advanced therapies \[biologics (TNF inhibitors, anti-integrin... Read More
Gender:
ALL
Ages:
16 years and above
Trial Updated:
07/25/2024
Locations: Iowa Digestive Disease Center, Clive, Iowa
Conditions: Ulcerative Colitis
iotaSOFT Pediatric Study
Recruiting
Prospective, non-randomized, open-label study to evaluate the safety and efficacy of the iotaSOFT Insertion System when used to assist electrode array insertion during cochlear implant surgery in a pediatric population.
Gender:
ALL
Ages:
Between 9 months and 12 years
Trial Updated:
07/23/2024
Locations: University of Iowa, Iowa City, Iowa
Conditions: Hearing Loss, Sensorineural, Hearing Loss, Bilateral, Hearing Loss, Unilateral
Autoimmune Intervention Mastery Course Study
Recruiting
The goal of this project is to critically evaluate the effectiveness of using an online program to improve diet and self-care in patients with multiple sclerosis (MS), clinically isolated syndrome (CIS), fibromyalgia, post acute sequela of covid, and cancer in remission with persisting fatigue.
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
07/22/2024
Locations: Univeristy of Iowa, Iowa City, Iowa
Conditions: Multiple Sclerosis, Clinically Isolated Syndrome, Fibromyalgia, Post Acute Sequelae of COVID-19, Cancer in Remission With Persisting Fatigue
A Comparison Of Primary TKA Rehabilitation Using A Smart Orthotic Versus Outpatient Physical Therapy
Recruiting
This will be a prospective, randomized, noninferiority clinical trial comparing rehabilitation methods post-total knee arthroplasty (TKA). Population of interest is adult hip/knee clinic patients over age 18 who are indicated for unilateral primary total knee arthroplasty. All TKA patients are prescribed physical therapy (PT) for rehabilitation post-operatively. The investigators will compare this current treatment with a new, validated, wearable smart knee brace (FM2 Knee Brace) that can be use... Read More
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
07/18/2024
Locations: University of Iowa Hospitals & Clinics, Iowa City, Iowa
Conditions: Arthropathy of Knee
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Recruiting
This is a Phase 1/2, open-label, non-randomized, 4-part trial to determine the safety profile and identify the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of INBRX 106 administered as a single agent or in combination with the anti-PD-1 checkpoint inhibitor (CPI) pembrolizumab (Keytruda®). KEYTRUDA is a registered trademark of Merck Sharp \& Dohme LLC, a subsidiary of Merck \& Co., Inc., Rahway, NJ, USA.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/17/2024
Locations: University of Iowa, Iowa City, Iowa
Conditions: Solid Tumor, Non-Small Cell Lung Cancer, Melanoma, Head and Neck Cancer, Gastric Cancer, Renal Cell Carcinoma, Urothelial Carcinoma
Essential Amino Acid Supplementation for Femoral Fragility Fractures
Recruiting
This trial will evaluate the impact of 4 weeks of postoperative essential amino acid (EAA)-based supplementation on muscle morphology after femoral fragility fracture. This trial will assess the ability of EAA-based to increase skeletal muscle metabolic activity, reduce inflammation, and induce muscle fiber hypertrophy, as well as preserve skeletal muscle mass and physical performance up to 6 months after injury. Participants will be randomized in a 1:1 ratio to 1) standard of care (no dietary i... Read More
Gender:
ALL
Ages:
65 years and above
Trial Updated:
07/15/2024
Locations: University of Iowa Health Care, Iowa City, Iowa
Conditions: Femoral Fracture, Fragility Fracture, Muscle Atrophy
Comparing Dara-VCD Chemotherapy Plus Stem Cell Transplant to Dara-VCD Chemotherapy Alone for People Who Have Newly Diagnosed AL Amyloidosis
Recruiting
This phase III trial compares the effect of adding a stem cell transplant with melphalan after completing chemotherapy with daratumumab, cyclophosphamide, bortezomib and dexamethasone (Dara-VCD) versus chemotherapy with Dara-VCD alone for treating patients with newly diagnosed amyloid light chain (AL) amyloidosis. Melphalan is a chemotherapy given prior to a stem cell transplant. Giving chemotherapy before a peripheral blood stem cell transplant helps kill cancer cells in the body and helps make... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/05/2024
Locations: Mission Cancer and Blood - Ankeny, Ankeny, Iowa
Conditions: AL Amyloidosis
Carboplatin Chemotherapy Before Surgery for People With High-Risk Prostate Cancer and an Inherited BRCA1 or BRCA2 Gene Mutation
Recruiting
This phase II trial tests how well carboplatin before surgery works in treating patients with high-risk prostate cancer and an inherited BRCA1 or BRCA2 gene mutation. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping, or slowing the growth of tumor cells. Giving carboplatin before surgery may shrink tumors in patients with h... Read More
Gender:
MALE
Ages:
18 years and above
Trial Updated:
07/05/2024
Locations: Alegent Health Mercy Hospital, Council Bluffs, Iowa
Conditions: Prostate Adenocarcinoma, Stage IIIB Prostate Cancer AJCC v8, Stage IIIC Prostate Cancer AJCC v8
Implementing Models for Mechanical Circulatory Support Presurgical Assessment in Congenital Heart Disease Treatment
Recruiting
The purpose of this research study is to look at the advantages of using a 3D printed heart model for surgical planning in children who have been diagnosed with Congenital Heart Disease (CHD) and clinical heart failure and will undergo a ventricular assist device (VAD) placement. The investigators want to study the correlation of having a 3D printed model with improvement in patient outcomes and compare those with patients who have had a VAD placement without a 3D model.
Gender:
ALL
Ages:
All
Trial Updated:
07/03/2024
Locations: University of Iowa, Iowa City, Iowa
Conditions: Congenital Heart Disease
Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)
Recruiting
This randomized phase III trial studies how well crizotinib works in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma kinase (ALK). Mutations, or changes, in ALK can make it very active and important for tumor cell growth and progression. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working. Crizotinib may be an effective treatment for patients with non-sma... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/29/2024
Locations: Mary Greeley Medical Center, Ames, Iowa
Conditions: ALK Gene Rearrangement, ALK Gene Translocation, ALK Positive, Stage IB Non-Small Cell Lung Carcinoma AJCC v7, Stage II Non-Small Cell Lung Cancer AJCC v7, Stage IIA Non-Small Cell Lung Carcinoma AJCC v7, Stage IIB Non-Small Cell Lung Carcinoma AJCC v7, Stage IIIA Non-Small Cell Lung Cancer AJCC v7